BIVDA Press Releases

15Jan

BIVDA response to Parliament’s vote on the Brexit deal

Today the House of Commons voted down the EU withdrawal agreement and the framework for the future relationship.

Doris-Ann Williams, BIVDA’s Chief Executive, commented: “Today’s vote casts a shadow of uncertainty over the UK’s future relationship with the EU. The IVD industry remains anxious about access for patients to essential diagnostic tests if there is no transition period after 29 March. We therefore call for positive steps to be taken in these testing times and urge Government and policy makers to provide clarity and create sufficient space for our sector so that it is able to meet the significant challenge of ensuring the supply of essential diagnostics tests to patients through 2019.”

For a copy of BIVDA's position paper on Brexit, click here.

Related

BIVDA Response to the Life Sciences Sector Deal

Commenting on the publication of the Life Sciences Sector Deal (6th December 2017), BIVDA’s Chief E...

Read More >

UK continues to lag behind the European market for in-vitro diagnostic expenditure

IVD Market Statistics Report 2017 highlights differences in total healthcare expenditure and wide va...

Read More >

All Party Parliamentary Group to raise the profile of the UK Life Sciences sector

This week marked the relaunch of the All Party Parliamentary Group (APPG) for Life Sciences.

Read More >

BIVDA Welcomes AAR Funding Announcement

Commenting on the Government’s announcement today (14 July 2017) regarding funding for the Accelera...

Read More >

Industry AMR Declaration Launched by BIVDA

The British In Vitro Diagnostics Association (BIVDA) has today (15 November) launched its In Vitro D...

Read More >

BIVDA comments on Parliament’s vote on the EU withdrawal agreement

Doris-Ann Williams, Chief Executive of BIVDA, comments on today's vote

Read More >